胰腺癌的肿瘤内在激酶组图谱揭示了新的治疗方法。
Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches.
作者信息
Xu Yi, Peng Xianlu L, East Michael P, McCabe Ian C, Stroman Grace C, Jenner Madison R, Chan Priscilla S, Morrison Ashley B, Shen Emily C, Hererra Silvia G, Joisa Chinmaya U, Rashid Naim U, Iuga Alina C, Gomez Shawn M, Miller-Phillips Lisa, Boeck Stefan, Heinemann Volker, Haas Michael, Ormanns Steffen, Johnson Gary L, Yeh Jen Jen
机构信息
Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
出版信息
Cancer Discov. 2025 Feb 7;15(2):346-362. doi: 10.1158/2159-8290.CD-23-1480.
Abstract
We provide a comprehensive tumor-intrinsic kinome landscape that provides a roadmap for the use of kinase inhibitors in PDAC treatment approaches.
摘要
我们提供了一个全面的肿瘤内在激酶组图谱，为在胰腺癌治疗方法中使用激酶抑制剂提供了路线图。
相似文献
1
Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches.胰腺癌的肿瘤内在激酶组图谱揭示了新的治疗方法。
Cancer Discov. 2025 Feb 7;15(2):346-362. doi: 10.1158/2159-8290.CD-23-1480.
2
Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines.激酶组状态可预测胰腺癌肿瘤和癌相关成纤维细胞系的细胞活力。
PeerJ. 2024 Aug 28;12:e17797. doi: 10.7717/peerj.17797. eCollection 2024.
3
A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR.一种针对MEK、BCL-xL和EGFR的新型胰腺导管腺癌治疗方案。
Neoplasia. 2025 Jan;59:101070. doi: 10.1016/j.neo.2024.101070. Epub 2024 Nov 14.
4
G3BP2 promotes tumor progression and gemcitabine resistance in PDAC via regulating PDIA3-DKC1-hENT in a stress granules-dependent manner.G3BP2通过以应激颗粒依赖的方式调节PDIA3-DKC1-hENT，促进胰腺导管腺癌（PDAC）的肿瘤进展和吉西他滨耐药。
Acta Pharmacol Sin. 2025 Feb;46(2):474-488. doi: 10.1038/s41401-024-01387-5. Epub 2024 Sep 17.
5
Development of a novel PIK3CA-mutated pancreatic tumor mouse model and evaluation of the therapeutic effects of a PI3K inhibitor.新型PIK3CA突变型胰腺肿瘤小鼠模型的建立及PI3K抑制剂治疗效果的评估
PLoS One. 2025 Jul 10;20(7):e0326491. doi: 10.1371/journal.pone.0326491. eCollection 2025.
6
Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer.同时抑制RAS-MAPK通路和PIKfyve是一种胰腺癌治疗策略。
Cancer Res. 2025 Apr 15;85(8):1479-1495. doi: 10.1158/0008-5472.CAN-24-1757.
7
Efficacy of SOAT1 Inhibitors Against Pancreatic Cancer with TP53 Mutations.SOAT1抑制剂对具有TP53突变的胰腺癌的疗效。
Ann Surg Oncol. 2025 May 30. doi: 10.1245/s10434-025-17482-8.
8
Phosphorylation of USP32 by CDK5 regulates Rap1 stability and therapeutic resistance in pancreatic ductal adenocarcinoma.CDK5介导的USP32磷酸化调控胰腺导管腺癌中Rap1的稳定性及治疗抗性
Oncogene. 2025 May 16. doi: 10.1038/s41388-024-03263-2.
9
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.细胞外基质微环境和肿瘤微环境增强 KRAS 抑制剂在胰腺癌中的疗效。
Cancer Res. 2024 Apr 1;84(7):1115-1132. doi: 10.1158/0008-5472.CAN-23-2504.
10
PLAGL2 as a prognostic biomarker and an EMT-promoting factor in PDAC.PLAGL2作为胰腺癌的一种预后生物标志物和上皮-间质转化促进因子。
Sci Rep. 2025 Jul 14;15(1):25425. doi: 10.1038/s41598-025-09591-x.
引用本文的文献
1
Experimental models of pancreas cancer: what has been the impact for precision medicine?胰腺癌的实验模型：对精准医学有何影响？
J Clin Invest. 2025 Aug 15;135(16). doi: 10.1172/JCI191945.
2
ERK signaling promotes IKKε expression and oncogenic functions in pancreatic cancer cells in association with TBK1.ERK信号传导与TBK1共同促进胰腺癌细胞中IKKε的表达及致癌功能。
J Biol Chem. 2025 Jul 28;301(9):110535. doi: 10.1016/j.jbc.2025.110535.
3
Evolving concepts in adjuvant/neoadjuvant therapy for resectable pancreas cancer.可切除胰腺癌辅助/新辅助治疗的概念演变
J Clin Invest. 2025 Jul 15;135(14). doi: 10.1172/JCI191944.
本文引用的文献
1
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.致癌 KRAS 抑制在胰腺癌中的耐药机制。
Cancer Discov. 2024 Nov 1;14(11):2135-2161. doi: 10.1158/2159-8290.CD-24-0177.
2
Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ.不同阶段尿路上皮膀胱癌的蛋白质基因组学研究揭示了乳头状癌和原位癌的不同分子特征。
Nat Commun. 2023 Sep 13;14(1):5670. doi: 10.1038/s41467-023-41139-3.
3
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.在 PDAC 患者接受新辅助化疗后，持久细胞表型导致预后不良。
Nat Cancer. 2023 Sep;4(9):1362-1381. doi: 10.1038/s43018-023-00628-6. Epub 2023 Sep 7.
4
TNIK is a conserved regulator of glucose and lipid metabolism in obesity.TNIK 是肥胖症中葡萄糖和脂质代谢的保守调节剂。
Sci Adv. 2023 Aug 9;9(32):eadf7119. doi: 10.1126/sciadv.adf7119.
5
Sub-Cluster Identification through Semi-Supervised Optimization of Rare-Cell Silhouettes (SCISSORS) in single-cell RNA-sequencing.基于单细胞 RNA 测序中稀有细胞轮廓的半监督优化（SCISSORS）的子聚类识别。
Bioinformatics. 2023 Aug 1;39(8). doi: 10.1093/bioinformatics/btad449.
6
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.人表皮生长因子受体 2 检测在乳腺癌中的应用：ASCO-美国病理学家学会指南更新。
J Clin Oncol. 2023 Aug 1;41(22):3867-3872. doi: 10.1200/JCO.22.02864. Epub 2023 Jun 7.
7
Transwell In Vitro Cell Migration and Invasion Assays.Transwell 体外细胞迁移和侵袭实验。
Methods Mol Biol. 2023;2644:349-359. doi: 10.1007/978-1-0716-3052-5_22.
8
An atlas of substrate specificities for the human serine/threonine kinome.人类丝氨酸/苏氨酸激酶组的底物特异性图谱
Nature. 2023 Jan;613(7945):759-766. doi: 10.1038/s41586-022-05575-3. Epub 2023 Jan 11.
9
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.FDA 批准的小分子蛋白激酶抑制剂的特性：2023 年更新。
Pharmacol Res. 2023 Jan;187:106552. doi: 10.1016/j.phrs.2022.106552. Epub 2022 Nov 17.
10
Internal Standard Triggered-Parallel Reaction Monitoring Mass Spectrometry Enables Multiplexed Quantification of Candidate Biomarkers in Plasma.内标触发平行反应监测质谱法可实现血浆中候选生物标志物的多重定量分析。
Anal Chem. 2022 Jul 12;94(27):9540-9547. doi: 10.1021/acs.analchem.1c04382. Epub 2022 Jun 29.
Zotero 插件